580 related articles for article (PubMed ID: 15019389)
1. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
[TBL] [Abstract][Full Text] [Related]
2. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
Lopez-Gonzalez R; Loza E; Jover JA; Benitez Del Castillo JM; Mendez R; Hernandez-Garcia C; Pato E
Scand J Rheumatol; 2009; 38(1):58-62. PubMed ID: 18991187
[TBL] [Abstract][Full Text] [Related]
3. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
4. Retrospective case review of pediatric patients with uveitis treated with infliximab.
Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
[TBL] [Abstract][Full Text] [Related]
5. Infliximab in the treatment of refractory posterior uveitis.
Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ
Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
[TBL] [Abstract][Full Text] [Related]
7. Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome.
Kiss S; Letko E; Qamruddin S; Baltatzis S; Foster CS
Ophthalmology; 2003 Sep; 110(9):1764-9. PubMed ID: 13129875
[TBL] [Abstract][Full Text] [Related]
8. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
10. Infliximab therapy for the treatment of refractory ocular inflammatory disease.
Sobrin L; Kim EC; Christen W; Papadaki T; Letko E; Foster CS
Arch Ophthalmol; 2007 Jul; 125(7):895-900. PubMed ID: 17620567
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital.
Petropoulos IK; Vaudaux JD; Guex-Crosier Y
Klin Monbl Augenheilkd; 2008 May; 225(5):457-61. PubMed ID: 18454398
[TBL] [Abstract][Full Text] [Related]
13. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
[TBL] [Abstract][Full Text] [Related]
14. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
15. Favorable response to high-dose infliximab for refractory childhood uveitis.
Kahn P; Weiss M; Imundo LF; Levy DM
Ophthalmology; 2006 May; 113(5):860-4.e2. PubMed ID: 16545455
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
17. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
Tabbara KF; Al-Hemidan AI
Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
[TBL] [Abstract][Full Text] [Related]
18. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.
Simonini G; Zannin ME; Caputo R; Falcini F; de Martino M; Zulian F; Cimaz R
Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502
[TBL] [Abstract][Full Text] [Related]
19. Infliximab for chronic cystoid macular edema associated with uveitis.
Markomichelakis NN; Theodossiadis PG; Pantelia E; Papaefthimiou S; Theodossiadis GP; Sfikakis PP
Am J Ophthalmol; 2004 Oct; 138(4):648-50. PubMed ID: 15488796
[TBL] [Abstract][Full Text] [Related]
20. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
